Stifel downgrades CoreWeave despite raising price target

Stifel downgrades CoreWeave (CRWV) from “Buy” to “Hold”, pointing to near-term risks following the company’s $9 billion acquisition of Core Scientific. Despite the downgrade, the firm raised its price target from $75 to $115, reflecting long-term optimism.

Analysts noted that while the deal offers strategic benefits like power control and infrastructure ownership, the integration of Core Scientific’s operations introduces uncertainty that could weigh on the stock in the short term.